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Purpose: Although many lung cancers express the epidermal
growth factor receptor and the vascular endothelial growth factor,
only a small fraction of patients will respond to inhibitors of these
pathways. Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MS) has shown promise in biomarker discovery,
potentially allowing the selection of patients who may benefit from
such therapies. Here, we use a matrix-assisted laser desorption/
ionization MS proteomic algorithm developed from a small dataset
of erlotinib-bevacizumab treated patients to predict the clinical
outcome of patients treated with erlotinib alone.
Methods: Pretreatment serum collected from patients in a phase I/II
study of erlotinib in combination with bevacizumab for recurrent or
refractory non-small cell lung cancer was used to develop a pro-
teomic classifier. This classifier was validated using an independent
treatment cohort and a control population.
Result: A proteomic profile based on 11 distinct m/z features was
developed. This predictive algorithm was associated with outcome
using the univariate Cox proportional hazard model in the training
set (p 0.0006 for overall survival; p 0.0012 for progression-free
survival). The signature also predicted overall survival and progres-
sion-free survival outcome when applied to a blinded test set of
patients treated with erlotinib alone on Eastern Cooperative Oncol-
ogy Group 3503 (n  82, p  0.0001 and p  0.0018, respectively)
but not when applied to a cohort of patients treated with chemother-
apy alone (n  61, p  0.128).
Conclusion: The independently derived classifier supports the hy-
pothesis that MS can reliably predict the outcome of patients treated
with epidermal growth factor receptor kinase inhibitors.
Key Words: Lung cancer, Biomarkers, Proteomics.
(J Thorac Oncol. 2009;4: 689–696)
Recent advances in our understanding of cancer biology haveled to the development of therapeutics that target pathways
important for tumor growth and survival. One such pathway
involves epidermal growth factor receptors (EGFRs). High
EGFR expression is often observed in non-small cell lung
cancer (NSCLC) and has been associated with a poor prog-
nosis. Targeting this pathway with the EGFR tyrosine kinase
inhibitor (EGFR-TKI) erlotinib confers a survival benefit for
patients with advanced lung cancer.1 Another pathway im-
portant for tumor growth involves the vascular endothelial
growth factor (VEGF), a major regulator of angiogenesis, and
thus represents an ideal target for therapeutic intervention.
VEGF expression is up-regulated in many solid tumors and is
an independent predictor of poor prognosis in patients with
NSCLC.2 A survival benefit is observed when bevacizumab,
a humanized monoclonal antibody targeting VEGF, is com-
bined with chemotherapy in patients with advanced lung
cancers.3 Given their vital roles in tumor growth and survival,
targeting the EGFR and vascular endothelial growth factor
receptor pathways represents a rational approach toward the
treatment of NSCLC.
Recent results from a randomized phase II trial evalu-
ating the combination of bevacizumab and erlotinib without
chemotherapy demonstrated that approximately 50% of pa-
tients derived clinical benefit from this treatment.4 The other
50% were exposed to toxicities whereas deriving no benefit.
EGFR mutations, increased EGFR gene copy number, k-ras
mutations, and overexpression of the EGFR protein have been
explored as predictive markers for the response to treatment
response with EGFR-TKIs. To date, EGFR mutations, copy
number, and EGFR expression levels have been predictive of
the response or the survival in some studies.5 EGFR gene
copy number was also predictive for the EGFR-TKI response
in the second and third line settings.6 These biomarkers
require tumor tissue analysis and are not sufficiently conclu-
sive for routinely selected patients who would derive benefits
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from therapy with EGFR-TKI. In addition, although there are
candidate markers to predict response to erlotinib treatment,
no markers are available to predict benefit from bevacizumab.
Despite considerable evidence for the association of intratu-
moral and/or plasma VEGF levels with tumor progression
and/or poor prognosis, pretreatment VEGF levels are not
predictive of response to bevacizumab therapy.7 Thus, better
prediction tools are needed to maximize treatment benefits
while minimizing toxicity.
Matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) can be used to generate
protein signatures from biologic specimens such as tissue,
urine, and serum. The technique also offers the advantages of
rapidity and sensitivity. Unfortunately, previous studies with
serum MS proteomics as biomarkers have suffered from the
lack of reproducibility and validation. These problems have
led to general skepticism about this technology and its use in
the development of cancer biomarkers.8 Recently, utilizing
serum MALDI-TOF MS, Taguchi et al.9 reported a proteomic
signature that independently classified patients according to
their clinical outcome after treatment with EGFR-TKI ther-
apy, but not with chemotherapy. This finding suggests that
MALDI-TOF MS may still be useful for biomarker develop-
ment and eventual clinical utility. In the present study, we
developed another independent proteomic signature obtained
from patients treated with erlotinib and bevacizumab that can
not only accurately classify this group of patients based on
clinical outcome in a leave-one-out analysis, but also can be
used to independently classify outcome in patients treated
with erlotinib alone. Furthermore, despite the small training
set, the variability of signals between obtained spectra was
small, suggesting that data generated from MS are reliable
and reproducible. This study thus lends further support to the
use of serum MALDI-TOF in biomarker discovery.
METHODS
Patients and Samples
MS was performed on pretreatment serum samples
from patients who were treated with erlotinib and bevaci-
zumab in an open-label, phase I/II study. Forty patients were
enrolled in this study. All were diagnosed with histologically
proven stage IIIB (with pleural effusion) or stage IV, recur-
rent, nonsquamous NSCLC. Pretreatment patient samples
were available for 37 of 40 patients in the clinical trial.
Further details regarding the patient population and the clin-
ical trial were described previously.4 The validation cohort
(n  82) comprised of patients enrolled in Eastern Cooperative
Oncology Group (ECOG) 350. The Vanderbilt University con-
trol group patients were comprised of unselected patients treated
under various institutional review board approved chemotherapy
protocols at Vanderbilt University Medical Center.9 These pa-
tients were treated in both the first and second line settings. None
were treated with EGFR-TKI at time of relapse.
Sample Preparation and Mass Spectrometry
The sera were thawed on ice and diluted 1:20 in a
saturated sinapinic acid solution (35 mg/ml sinapinic acid
(Sigma, St. Louis, MO), 50% acetonitrile (Burdick & Jack-
son, Muskegon, MI), and 0.1% trifluoroacetic acid (Sigma,
St. Louis, MO)). To avoid confounding variables associated
with the run order, samples were randomly spotted in tripli-
cate, placed on gold 64-well sample plates, and allowed to
dry at room temperature. Mass spectra for all samples were
generated in linear mode using a Voyager-DE STR worksta-
tion. The results from 500 to 525 independent spectrum acqui-
sitions per sample were averaged to generate each spectrum. To
avoid day-to-day bias, the spectrometry of all triplicate sam-
ples was repeated on two other days (for a total of 3 days). All
mass spectra were output as column text files of intensity
versus mass/charge (m/z). Mass spectra from ECOG 3503
and the Vanderbilt control cohort were obtained from Dr.
David P. Carbone.9
Spectral Preprocessing
Raw spectra were analyzed with Wave-spec software
developed at the Vanderbilt University High Dimensional
Data Analysis Center. Detailed information on preprocessing
was published previously.10 Briefly, preprocessing comprised
of internal calibration, smoothing, baseline correction, nor-
malization to the total ion current, feature selection based on
signal-to-noise ratio, and binning of features. Internal cali-
bration was performed using the Apo-C1 (m/z  6631),
hemoglobin (m/z  15127), hemoglobin  chain (m/z 
15127), and two unidentified, common peaks m/z 9423 and
m/z  13746. A total of 174 bins were selected from m/z
ratios between 3000 and 20,000. The preprocessing parame-
ters were optimized based on the training set and were fixed
when applied to the preprocessing of the independent test set.
Experimental Reproducibility and Variability
Determination
Experimental variability and reproducibility (both ana-
lytical and biologic) were first tested on 277 spectra generated
from 37 available serum samples. We used Coefficients of
Variation (CV) as a measure of the relative variability be-
tween the expression levels of each peak or feature. We also
used a nested, random-effect model, testing the variability not
only between patients, but also with the acquisition day factor
nested within each patient. The intraclass correlation coeffi-
cient (ICC), a measure of correlation, consistency, or confor-
mity for a dataset when it contains multiple groups, is defined
by the expression:
ICC  inter
2 /(inter
2  intra
2 )
where inter
2 is the variance between patients and intra
2 is the
pooled variance within a patient and between days. The distri-
bution across peaks for CV, variance components, and ICC are
presented in quantiles and box-plots.
Risk Prediction Model
Serum sample were available from 37 of 40 patients
enrolled in the clinical trial. Of these, 35 provided both
spectral data and associated clinical data used to develop the
risk prediction model. Features or peaks associated with
survival were selected based on a univariate Cox regression
analysis, considering mean intensity for one feature at a time.
A false discovery rate of 0.05 was used as cutoff for
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selecting important features. Once significant features were
selected, the compound score (denoted as ci) for patient i was
defined as
ci  
j1
k
(sign of j) wjxj,i (1)
where xj,i is the peak intensity of the feature j for patient i, wj
is the Wald statistic, and j is the coefficient obtained with the
univariate Cox regression analysis for the set of k selected
significant features. The compound score (ci) is then used as
prediction index. A prediction model was then developed based
on the Cox model with the compound score as predictor,
hit  h0t exp ci) (2)
The compound score for a new patient with the vector of
intensity x1,i
* , . . ., xk,i
* ) for the selected features can be calcu-
lated by replacing xj,i with xj,i
* in (1), which is then used to
predict the survival time for that patient.
Validation of Prediction Model Using ECOG
and VU Control Cohorts
For the validation of the predictive power of the com-
pound score derived in (2), the Cox proportional hazards
(CPH) model was first fitted with this compound score as the
only covariate, whereas overall survival (OS) and progres-
sion-free survival (PFS) served as outcome variables, respec-
tively. After the univariate analysis, baseline clinical factors
were entered into the model along with the compound score
to determine whether the compound score could serve as an
independent predictor for survival.
For the VU control cohort, smoking status, stage, and
compound score were prespecified in the multivariable CPH
model. For the ECOG cohort, model building techniques
were used in four steps relying first on univariate testing for
each of the candidate variables. Only variables with a statis-
tical significance of p 0.2 were considered for the next step
of model building. Backward elimination, forward selection,
and stepwise selection (with p 0.1) were then performed on
the variables to select possible models. In the final stepwise
step, two-way interactions under the hierarchical principle
were also added for consideration in the model. The Akaike’s
information criterion was adopted to make comparisons
among a number of possible models. The smaller the value of
this statistic, the better the model fits the data.
The proportional hazards assumption of each covariate
was evaluated after model building using time-by-covariate
interactions. Model fitting was assessed via the Cox-Snell
generalized residuals plot and diagnostics for influential
points. OS and PFS survival curve for the subgroups of
categorized compound scores were estimated using the
Kaplan-Meier method. Analyses were performed using SAS
version 9.1 and R version 2.1.1.
RESULTS
Reproducibility of Data Processing
Patient characteristics from the three cohorts used for
testing and validation are summarized in Table 1. We gener-
ated 277 spectra from the available 37 samples in the erlo-
tinib/bevacizumab study. The average number of spectra per
patient was 7.5 (range, 5–9). Across all sera, 139 peaks in the
3,000 to 20,000 m/z range were detected. To quantify the
relative variability of the features or peaks, we generated
Coefficients of Variation (CV) using 139 common peaks for
all samples, and for samples from each of the 3 replicated
TABLE 1. Characteristics of the Non-Small Cell Lung Cancer Patients Cohorts
Characteristics
Bevacizumab/Erlotinib ECOG 3503 VU Control
(n  35a) (n  82) (n  61)
Sex (%)
Male 14 (40) 37 (45.1) 42 (68.9)
Female 21 (60) 45 (54.9) 19 (31.1)
Age (yr)
Median 59 70 65
Range 36–72 41–93 40–84
Stage
IIIB N/Ab 7 (8.5) 28 (45.9)
VI N/Ab 59 (72.0) 33 (54.1)
Recurrent 16 (19.5)
RECIST (%)
Partial response 8 N/A N/A
Stable disease 21 N/A N/A
Progressive disease 6 N/A N/A
Survival (mo)
Overall (95% CI) 15.25 (7.75-inf) 7.69 (5.39–10.05) 14.63 (10.3–27.27)
Progression-free (95% CI) 4 (2.25–12.5) 3.38 (2.07–3.91)
a The total number of patients with available clinical data for survival analysis.
b The total number of patients in the bevacizumab/erlotinib trial was 40 (seven IIIb, 32 IV, one unknown).
CI, confidence interval; N/A, not applicable; RECIST, Response Evaluation Criteria in Solid Tumors.
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days (Figure 1A). The comparable and low mean CV of 5%
across the 3 days and comparable overall CV suggest that the
spectra did not differ significantly and that our spectrometry was
reproducible. We used intraclass correlation coefficients (ICC)
to measure consistency and conformity among the multiple
groups within our training set. The obtained mean ICC of 0.5192
indicates a relatively large intrasample variability (Figure 1B);
therefore, nine replications of the same sample were measured to
reduce the heterogeneity of the expression profiles in each tumor
sample. Observed patient, day, and residual variance (a measure
of variability distribution) for the 139 common peaks in our
dataset are shown in Figure 1C.
MALDI-MS Algorithm Accurately Classifies
Outcomes for Patients Treated with
Erlotinib-Bevacizumab
Features associated with survival were selected using a
univariate CPH model, with peak intensity as covariate or
associated with clinical outcome. Eleven features were se-
lected according to their statistical significance, defined by a
false discovery rate 0.05 (Table 2). Using the Wald
statistic and peak intensities of these 11 features, a compound
score for each patient was generated. To illustrate that the
compound score can differentiate intensities of the 11 se-
lected features, we generated an intensity plot comparing the
mean peak intensity of the group with high intensity score,
defined as those with compound score  median compound
score (114.7862), to that from the group with low intensity
score (114.7862). The difference in mean intensities be-
tween the two groups is easily observed in peaks with m/z
values greater than 5000 (Figure 2A). At higher magnifica-
tion, differences within peak regions 4121, 4596, and 4821
can also be detected (Figure 2B). Although the two average
curves show negligible differences at peak 4710, some indi-
vidual spectra from samples with high compound scores dem-
onstrated disparate peaks at this value. Whether an identified
peak is a product of technology or biology will ultimately be
established by validation and perhaps protein identification.
Figure 2C shows a heatmap to better visualize the relationship
between the compound scores and peak intensities for the 11
selected features.
TABLE 2. List of 11 Distinct m/z Features Used to Predict
Clinical Outcome
m/z Lower m/z Upper m/z pFDR
1 4121 4112 4128 0.0482
2 4596 4581 4605 0.0857
3 4720 4717 4724 0.0476
4 4821 4804 4833 0.0445
5 5720 5714 5726 0.0362
6 5841 5832 5848 0.0447
7 11441 11423 11455 0.0396
8 11528 11515 11539 0.0483
9 11684 11673 11697 0.0368
10 11731 11717 11742 0.0345
11 11902 11890 11933 0.0381
pFDR, positive false discovery rate.
FIGURE 1. Reproducibility analysis
of the bevacizumab/erlotinib training
data set. A, Coefficient of variation
(CV) using 139 common peaks
across all sera in the 3000 to 20,000
m/z range. The results show low and
comparable CV across all days, sug-
gesting highly reproducible spectra.
B, Intraclass correlation coefficient
(ICC), a measure of reliability, is
0.5192, suggesting a good agree-
ment at all common peaks. C, A
summary of observed patient, day,
and residual variance (a measure of
variability distribution), for the 139
common peaks.
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MALDI-MS Algorithm Accurately Classifies
Clinical Outcome in Patients Treated with
Erlotinib-Containing Regimen
Using the univariate CPHmodel, the proteomic algorithm
based on the 11 distinct m/z features was found to be associated
with clinical outcome in both OS and PFS (p  0.0006 for OS;
p  0.0012 for PFS). We used the median scores to generate
binary data to improve data visualization. We found a tight
relationship between compound scores and clinical outcome
when we compared the survival of patients whose compound
scores were less than the median (114.7862) to the survival of
those whose scores were equal or greater. The Kaplan–Meier
survival curves for the two groups are shown in Figure 3A. The
group with the scores that were lower than the median shows a
statistically significantly greater OS and PFS (log-rank test, p
0.00284 and p  0.014, respectively).
We applied the prediction algorithm to a validation cohort
from ECOG protocol E3503, a phase II trial of erlotinib. Each
patient was given a compound score based on our classification
algorithm, and the results were sent to the ECOG Statistical
Office for correlation with the clinical data. The analysis is
based on 82 patients, excluding ineligible patients and those
FIGURE 2. The intensity plots comparing the mean spectra of samples from the group with high versus the group with low com-
pound scores, respectively. A, Intensity plots for m/z regions 4000 to 5000, 5000 to 6000, and 11,000 to 12,000 demonstrating
different intensities among 11 features (blue lines). The black line denotes mean intensity of peaks from patients with compound
scores equal or less than the median. The red line represents mean intensity of peaks from patients whose compound scores were
greater than the median. B, Magnification of intensity plots for features 4121, 4596, 4720, and 4821 showing a subtle difference in
intensity between the mean spectrum with high and that with low compound score. C, A heatmap of the 11 peaks or features
from the bevacizumab/erlotinib training data set, ranked according to compound score. The levels of peak intensity (features 4121,
5720, 5841, 11,441, 11,528, 11,684, 11,731, and 11,902) increase as compound scores increase, whereas peak intensities of fea-
tures 4596, 4720, 4821 decrease.
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without an available compound score. With the obtained
proteomic signature, we were able to classify OS and PFS
outcome for samples from the blinded test set of patients
treated with erlotinib alone on ECOG 3503 (univariate CPH
model, p  0.0001 and p  0.0018, respectively). When the
compound scores were again sorted into two groups, one
whose scores were equal or above the median (131.0321) and
one below, patients with lower compound scores had better
OS and PFS than those whose prediction scores were higher
(log-rank test, p  0.0001 and p  0.003, respectively).
Figure 3B shows a Kaplan-Meier plot for OS and PFS.
Because the analyses were based on survival, it is
possible that the survival outcome classification derived from
the MALDI-TOF MS algorithm merely indicates perfor-
mance status or overall general health, and was not specific to
treatment with the erlotinib-containing regimen. To test
whether the profile was predictive or merely prognostic, we
used a control cohort of 61 patients with advanced NSCLC
who were treated with various chemotherapy regimens at
Vanderbilt University Medical Center, and for whom clinical
data and spectra were available.9 About 80% of these patients
received carboplatin and paclitaxel. No difference in OS was
noted between the two groups, one whose scores were equal or
above the median (133.2427) and one below (univariate CPH,
p  0.128 and log-rank test, p  0.181) (Figure 3C). These
findings suggest that our MS algorithm is predictive of patients
who would benefit from erlotinib, and not merely prognostic.
However, further testing in a prospective, randomized setting is
needed to ascertain that this observation is not merely an artifact
due to the retrospective nature of our study.
To determine whether our profiles have independent
predictive ability in outcome for patients treated with bevaci-
zumab/erlotinib, we tested our proteomic algorithm, using the
CPH model with the adjustment of common baseline factors.
After adjusting for age, sex, and histology, our predictors
remained significant for OS and PFS. In the ECOG cohort,
the predictors held after adjustment for the number of meta-
static sites and performance status. The results obtained using
multivariate model for the different cohorts including that for
VU Control are summarized in Table 3.
FIGURE 3. Survival of patients
from the training, testing, and con-
trol datasets sorted by median
compound score using Kaplan-
Meier analysis. Overall survival (OS)
and progression-free survival (PFS)
of patients, whose compound
scores were less than the median
were significantly better than those
of patients whose scores are equal
or greater than the median in bev-
acizumab/erlotinib (A) and ECOG
3503 (B) cohorts. (C) OS of VU
control cohort based on median
score.
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DISCUSSION
In the present study, we developed a novel MALDI-
TOF MS survival prediction model with which NSCLC
patients can be identified who may benefit from treatment
with an erlotinib-containing regimen. To develop this model,
a training set of 37 patients treated with bevacizumab and
erlotinib was used. Despite the small sample size, the model
retained its predictive abilities on multivariate testing against
the ECOG 3503 validation cohort. By contrast, we could not
classify patients treated with chemotherapy alone, suggesting
that it is not merely prognostic, but moreover predictive for
outcome in patients treated with EGFR inhibition with or
without bevacizumab. Though our findings are encouraging,
we cannot rule out that potential confounders and selection
bias due to the retrospective nature of our study may result in
an incorrect estimate of the association between the algorithm
and clinical outcome.
There is a dearth of practical and clinically useful
biomarkers for diagnosis, prognosis, and disease monitoring
in lung cancer. Early studies using MS to develop proteomic
profiles from patient sera, coupled with advanced data mining
algorithms had triggered hopes that this technology could be
used for cancer diagnosis, prognosis, and disease/treatment
monitoring.11 The enthusiasm for this technology has dimin-
ished due to the lack of reproducibility, procedural bias, and
virtually no independent confirmation.8,12 Although the two
current proteomic technologies MALDI-TOF MS and sur-
face-enhanced laser desorption and ionization MS may differ
in their approaches and sensitivity, the potential pitfall in-
volving data reproducibility remains a significant universal
concern. To avoid systematic or procedural bias in our study,
the positions on the plates were randomized, and the sample
spectrometry was replicated a total of nine times and on
multiple days. Despite the relatively small dataset, the low
and consistent coefficient variation among peaks, low vari-
ance, and high intraclass correlation affirm the potential for
reproducibility of proteomic approaches.
Interestingly, while the patients in our cohort were
treated with bevacizumab and erlotinib, our predictors could
accurately classify patients from ECOG 3503 who were
treated with erlotinib alone. Furthermore, of the 11 mass
spectral features identified in our study, five overlap with
those from another independent, proteomic algorithm devel-
oped by Taguchi et al.9 Their model was based on patients
treated with erlotinib alone. Because there has been no
demonstrated clinical efficacy for bevacizumab alone in hu-
man lung cancer, it is reasonable to propose that the predic-
tive power of the classifier is the result of direct augmentation
of the erlotinib activity by bevacizumab. It is also possible
that the addition of bevacizumab to the erlotinib treatment in
our training set, compared with the erlotinib-only population
from Taguchi et al., may account for the incomplete overlap
of mass spectral features. These hypotheses will need to be
tested against patients treated with erlotinib/bevacizumab and
erlotinib alone. Unfortunately, such samples are not yet avail-
able to us. Nevertheless, validation of our predictors using the
ECOG independent dataset and the identification of similar
discriminant mass spectral features in another independent al-
gorithm suggest that our observations most likely reflect biology
and not simply data overfitting.
Finally, although we have not yet identified the proteins
represented by our 11 selected features, our proteomic signa-
ture is unable to predict outcome in the chemotherapy-treated
cohort. This finding suggests that the selected features represent
proteins that are not just stress-related. Of note, a number of
current biomarkers used for cancer screening and treatment
monitoring such as CA-125, prostate-specific antigen, and CA-
19-9 have no direct role in cancer pathogenesis. Thus, it is highly
possible that the proteins we have identified as predictive will
not give insights into pathways or mechanisms of disease or
TABLE 3. Multivariable Analysis for Patient Data Sets
Factor
OS PFS
Hazard Ratio
(95% CI) p Hazard Ratio (95% CI) p
Erlotinib/bevacizumab
Compound score 1.024 (1.009–1.040) 0.003 1.016 (1.005–1.028) 0.004
Age 0.992 (0.933–1.056) 0.809 0.979 (0.936–1.024) 0.347
Sex 1.022 (0.328–3.185) 0.97 0.893 (0.345–2.310) 0.815
Adeno vs. nonadeno 1.679 (0.540–5.223) 0.371 0.933 (0.318–2.736) 0.899
ECOG 3503
Compound score 1.012 (1.003–1.021) 0.012 1.014 (1.004–1.024) 0.006
Metastatic site 1.414 (1.191–1.678) p  0.0001 1.298 (1.086–1.552) 0.004
PS  0 vs. PS  2 0.227 (0.109–0.473) p  0.0001 NA
PS  1 vs. PS  2 0.388 (0.209–0.791) 0.003 NA
VU control
Compound score 1.011 (0.996–1.026) 0.161 NA
Ex-smoker vs. current 0.525 (0.233–1.181) 0.119 NA
Nonsmoker vs. smoker 0.879 (0.192–4.019) 0.868 NA
Stage IV vs. IIIB 0.714 (0.369–1.488) 0.4 NA
OS, overall survival; PFS, progression-free survival, CI, confidence interval; NA, not applicable.
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treatment response. Clearly, only further rigorous testing in a
prospective clinical trial setting can determine whether any
candidate biomarker will have clinical utility regardless of its
identification.
In summary, we have demonstrated that a small dataset
can be used to develop a prediction model using MALDI-
TOF MS from the sera of patients with NSCLC. With sample
randomization and replication, we were able to avoid extreme
sample variations and systemic biases. Furthermore, our model
could accurately and independently identify patients who may
benefit from treatment with an erlotinib-containing regimen.
Although further validation with independent, larger cohorts is
needed, our findings affirm that MS can be a useful tool in
biomarker discovery.
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